WHOOP Valuation Soars to $10.1B After $575M Funding Round

WHOOP, a leader in physiological monitoring wearables, has finalized a substantial $575 million Series G funding round, achieving a commanding $10.1 billion valuation. This latest capital infusion nearly triples the company's valuation from its previous funding in 2021, signaling robust investor confidence in its advanced health platform. The significant investment underscores the growing market demand for personalized health insights driven by sophisticated wearable technology.

The financing was spearheaded by Collaborative Fund and saw extensive participation from a prestigious roster of global investors. Key institutional backers include Mubadala Investment Company, Qatar Investment Authority, Abbott, Mayo Clinic, IVP, Foundry Group, Accomplice, Affinity Partners, 2Point2Zero Group, Glade Brook, B-Flexion, Macquarie Capital, Promus Ventures, and Bullhound Capital. The round also attracted notable individual investors such as athletes Cristiano Ronaldo, LeBron James, Rory McIlroy, Reggie Miller, and Niall Horan, highlighting the broad appeal of WHOOP's mission.

With over 2.5 million members worldwide, WHOOP has demonstrated impressive commercial traction, reporting a $1.1 billion bookings run rate, which represents a remarkable 103% year-over-year growth in 2025. The company also achieved a significant operational milestone by becoming cash flow positive during 2025. This financial strength positions WHOOP favorably as it looks to scale its operations and product offerings.

The newly acquired capital will fuel aggressive international expansion into key markets including Europe, the Gulf Cooperation Council region, Latin America, and Asia. Furthermore, the company plans a significant global hiring initiative, aiming to add over 600 new roles, and will continue to invest heavily in enhancing its AI-driven health and performance analytics. This strategic deployment of funds is designed to solidify WHOOP's position as a global leader in proactive health management.

Beyond its core wearable offering, WHOOP is advancing its medical-grade capabilities with WHOOP MG, an FDA-cleared device providing electrocardiogram readings and blood pressure insights, alongside a unique 'WHOOP Age' feature. The company's innovative Advanced Labs service, which integrates blood testing with continuous biometric data via partnerships with Quest Diagnostics, currently has a waitlist of 350,000 individuals, indicating substantial unmet demand for integrated health diagnostics.

CEO Will Ahmed indicated that this Series G round is anticipated to be the company's final private financing endeavor, with an initial public offering (IPO) being the next strategic objective. Ahmed emphasized the caliber of investors and the company's commitment to both exceptional talent and cutting-edge AI tools as critical drivers of future success. The company's current valuation places it as a significant player in the wearable technology sector, comparable to established tech giants, and it is actively undertaking preparatory steps for a public market debut.